Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide
Author:
Affiliation:
1. Medical Oncology Department, Santa Chiara Hospital, Trento, Italy
2. Radiotherapy Department, Civil Hospital, Cremona, Italy
3. Medical Oncology Department, Civil Hospital, Merano, Italy
Abstract
Publisher
Future Medicine Ltd
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/fon.14.24
Reference25 articles.
1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
3. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
4. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
5. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study;Frontiers in Oncology;2024-06-04
2. Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein;Cell Death & Disease;2022-12-12
3. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer;Medical Science Monitor;2022-09-30
4. Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review;Cancers;2022-08-03
5. The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer;Anticancer Research;2021-12-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3